Literature DB >> 16319692

Real-time quantitative PCR analysis of regions involved in gene amplification reveals gene overdose in low-grade astrocytic gliomas.

Dolores Arjona1, M Josefa Bello, M Eva Alonso, Alberto Isla, Jose M De Campos, Jesus Vaquero, Jose L Sarasa, Manuel Gutierrez, Juan A Rey.   

Abstract

We have studied gene amplification of genes located in 1q32 (GAC1, ELF3, MDM4, and ren1), 4q11 (PDGFR-alpha), and in 12q13-14 (MDM2 and CDK4) using quantitative real-time PCR in a group of 86 tumors consisting of 44 WHO grade IV glioblastomas (GBM) (34 primary and 10 secondary tumors), 21 WHO grade III anaplastic astrocytomas (AA), and 21 WHO grade II astrocytomas (AII). Gene amplification was present in 56 of the 86 samples (65%) in at least 1 gene in our series. GAC1 (51%) and MDM4 (27%) were the most frequently amplified genes within the 1q32 amplicon, and their higher amplification frequency was statistically significant (P<0.05, chi) in the low-grade astrocytomas. Concordant co-amplification was determined for ELF3 and ren1 or ren1 and MDM4 in the grade III-IV tumors. MDM2 amplification was significantly more frequent in primary GBM (16%) than was in secondary GBM (0%). The present study shows that gene amplification in the studied regions is already present in low-grade astrocytic tumors and that amplification of some genes may represent another molecular marker to differentiate primary from secondary GBM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319692     DOI: 10.1097/01.pas.0000177799.58336.1a

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  6 in total

1.  Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo.

Authors:  Sarah De Clercq; Agnieszka Gembarska; Geertrui Denecker; Marion Maetens; Michael Naessens; Katharina Haigh; Jody J Haigh; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2010-09-20       Impact factor: 4.272

Review 2.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.

Authors:  Franck Toledo; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

3.  Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.

Authors:  Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Audrey Rousseau; Karima Mokhtari; Michèle Kujas; Younas El Houfi; Catherine Carpentier; Sophie Paris; Blandine Boisselier; Florence Laigle-Donadey; Joëlle Thillet; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Neuro Oncol       Date:  2008-06-10       Impact factor: 12.300

4.  Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.

Authors:  O Martinho; A Longatto-Filho; M B K Lambros; A Martins; C Pinheiro; A Silva; F Pardal; J Amorim; A Mackay; F Milanezi; N Tamber; K Fenwick; A Ashworth; J S Reis-Filho; J M Lopes; R M Reis
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

Review 5.  MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.

Authors:  Xanthene Miles; Charlot Vandevoorde; Alistair Hunter; Julie Bolcaen
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

6.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.

Authors:  Andrea Prodosmo; Simona Giglio; Sonia Moretti; Francesca Mancini; Flavia Barbi; Nicola Avenia; Giusy Di Conza; Holger J Schünemann; Lorenza Pistola; Vienna Ludovini; Ada Sacchi; Alfredo Pontecorvi; Efisio Puxeddu; Fabiola Moretti
Journal:  J Mol Med (Berl)       Date:  2008-03-12       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.